Sanof公布T1DM预防药Teplizumab对于新发T1DM的β细胞保护作用3期临床结果

PROTECT试验结果显示，在研究终点Teplizumab治疗组的C肽水平显著高于安慰剂组，平均高出0.13 pmol/mL。Teplizumab组94.9%的受试者能够维持C肽峰值水平≥0.2 pmol/mL，而安慰剂组为79.2%（p<0.001…

发布时间：2023-10-18浏览数：904

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association

Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the …

发布时间：2015-12-01浏览数：416

1型糖尿病分期标准

1型糖尿病（T1DM）分期标准不仅为临床实践也为T1DM预防药物，如抗CD3抗体药物的开发提供了重要的理论依据。

发布时间：2015-12-01浏览数：514